European telehealth firm HealthHero buys MyClinic.ieEuropean telehealth firm HealthHero has bought MyClinic.ie, a rival based in the Republic of Ireland. Already a major Share XEuropean telehealth firm HealthHero buys MyClinic.iehttps://pharmaphorum.com/news/european-telehealth-firm-healthhero-buys-myclinic-ie/
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelBoehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as Share XBoehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelhttps://pharmaphorum.com/news/boehringer-lillys-jardiance-ties-to-match-azs-farxiga-with-heart-failure-label/
RNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upsUS biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who Share XRNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upshttps://pharmaphorum.com/news/rnai-biotech-atalanta-debuts-with-110m-plus-biogen-and-roche-cns-tie-ups/
bluebird bio to split into oncology and gene therapy specialistsUS biotech bluebird bio has announced plans to split into two this year, with a separate oncology business Share Xbluebird bio to split into oncology and gene therapy specialistshttps://pharmaphorum.com/news/bluebird-bio-to-split-into-oncology-and-gene-therapy-specialists/
Chi-Med agrees R&D partnership with InmageneChina’s Chi-Med and Inmagene Biopharmaceuticals have agreed a strategic partnership to develop preclinical drug candidates for potential treatment Share XChi-Med agrees R&D partnership with Inmagenehttps://pharmaphorum.com/news/chi-med-agrees-rd-partnership-with-inmagene/
Sanofi buys UK’s Kymab and inflammatory disease hopeful for $1.45bnSanofi is to acquire UK biotech Kymab in a deal worth up to $1.45 billion as the big Share XSanofi buys UK’s Kymab and inflammatory disease hopeful for $1.45bnhttps://pharmaphorum.com/news/sanofi-buys-uks-kymab-and-inflammatory-disease-hopeful-for-1-45bn/
Bioclinica boosts digital trial credentials with Saliency buyWith the ink barely dry on its last merger agreement, clinical trial and imaging specialist Bioclinica is on Share XBioclinica boosts digital trial credentials with Saliency buyhttps://pharmaphorum.com/news/bioclinica-boosts-digital-trial-credentials-with-saliency-buy/
AmerisourceBergen buys Walgreens Boots Alliance wholesaling business for $6.5bnUS wholesale giant AmerisourceBergen is to buy the majority of Walgreens Boots Alliance’s wholesaling business for around $6.5 Share XAmerisourceBergen buys Walgreens Boots Alliance wholesaling business for $6.5bnhttps://pharmaphorum.com/news/amerisourcebergen-buys-walgreens-boots-alliance-wholesaling-business-for/
Moderna’s COVID-19 vaccine is third approved in UKThe UK has approved the Moderna coronavirus vaccine, hard on the heels of its go-ahead in Europe, although Share XModerna’s COVID-19 vaccine is third approved in UKhttps://pharmaphorum.com/news/modernas-covid-19-vaccine-is-third-approved-in-uk/
